Lyell Immunopharma, Inc. (LYEL)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGS
14.53 USD
-0.08
(-0.548%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 14.53 |
Hot Take ↕ | Aug. 22, 2026, 3:32 a.m. EDT
The investment case here is severely compromised by a catastrophic multi-year decline. The stock has lost 96.55% of its value over the last four years, with every single year showing negative returns. This is not a temporary correction; it is a structural implosion where the market has repeatedly rejected the business model. Fundamentals confirm the distress: revenue is contracting by half, profitability is nonexistent with massive operating losses, and the company is burning through cash with no visible path to positive free cash flow. While the balance sheet currently shows low debt relative to equity, this is likely due to the depressed share count rather than operational strength, and the company remains reliant on external capital. The short-term outlook remains bearish given the weak statistical forecast and defensive options positioning, though the extreme oversold condition creates a speculative 'buy the dip' narrative that ignores the high probability of continued deterioration. There is no dividend to provide income, and the long-term outlook is bleak until a viable product pipeline or revenue turnaround is demonstrated. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.175880 |
| MSTL | 0.251136 |
| AutoETS | 0.258204 |
| AutoARIMA | 0.260341 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 39% |
| H-stat | 0.30 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.615 |
| Excess Kurtosis | -0.71 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 19.929 |
| Revenue per Share | 0.001 |
| Market Cap | 356,059,680 |
| Forward P/E | -2.30 |
| Beta | -0.07 |
| Website | https://www.lyell.com |
As of Aug. 22, 2026, 3:32 a.m. EDT: Speculators are positioning defensively with heavy out-of-the-money put volume (108 contracts) expiring in October, suggesting a fear of further downside. Conversely, call activity is sparse and dominated by deep out-of-the-money strikes, indicating a lack of aggressive bullish conviction despite the low price.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.2734443 |
| Address1 | 201 Haskins Way |
| Address2 | Suite 101 |
| All Time High | 396.8 |
| All Time Low | 7.65 |
| Ask | 18.12 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 135,740 |
| Average Daily Volume3 Month | 188,934 |
| Average Volume | 188,934 |
| Average Volume10Days | 135,740 |
| Beta | -0.067 |
| Bid | 14.51 |
| Bid Size | 1 |
| Book Value | 9.993 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 14.53 |
| Current Ratio | 5.356 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 14.78 |
| Day Low | 14.06 |
| Debt To Equity | 19.929 |
| Display Name | Lyell Immunopharma |
| Earnings Timestamp End | 1,793,995,200 |
| Earnings Timestamp Start | 1,793,995,200 |
| Ebitda | -180,944,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.097 |
| Enterprise To Revenue | 7,353.915 |
| Enterprise Value | 198,555,696 |
| Eps Current Year | -6.92 |
| Eps Forward | -6.32 |
| Eps Trailing Twelve Months | -12.6 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 13.859 |
| Fifty Day Average Change | 0.6709995 |
| Fifty Day Average Change Percent | 0.048416156 |
| Fifty Two Week Change Percent | 27.344429 |
| Fifty Two Week High | 45.0 |
| Fifty Two Week High Change | -30.470001 |
| Fifty Two Week High Change Percent | -0.67711115 |
| Fifty Two Week Low | 10.763 |
| Fifty Two Week Low Change | 3.7670002 |
| Fifty Two Week Low Change Percent | 0.34999537 |
| Fifty Two Week Range | 10.763 - 45.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,623,936,600,000 |
| Float Shares | 12,155,040 |
| Forward Eps | -6.32 |
| Forward P E | -2.2990506 |
| Free Cashflow | -72,809,128 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 161 |
| Fullday Change | -0.0799999 |
| Fullday Change Percent | -0.54757 |
| Fullday Price | 14.53 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 27,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.37235 |
| Held Percent Institutions | 0.54201 |
| Implied Shares Outstanding | 24,505,141 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-06-17 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,748,822,400 |
| Last Split Factor | 1:20 |
| Long Business Summary | Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. |
| Long Name | Lyell Immunopharma, Inc. |
| Market | us_market |
| Market Cap | 356,059,680 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_590661061 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -248,476,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 358,020,110 |
| Number Of Analyst Opinions | 8 |
| Open | 14.56 |
| Operating Cashflow | -133,260,000 |
| Operating Margins | -11,834.25 |
| Payout Ratio | 0.0 |
| Phone | 650 695 0677 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 14.53 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 14.61 |
| Price Eps Current Year | -2.099711 |
| Price Hint | 2 |
| Price To Book | 1.4540178 |
| Price To Sales Trailing12 Months | 13,187.3955 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.12 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0799999 |
| Regular Market Change Percent | -0.54757 |
| Regular Market Day High | 14.78 |
| Regular Market Day Low | 14.06 |
| Regular Market Day Range | 14.06 - 14.78 |
| Regular Market Open | 14.56 |
| Regular Market Previous Close | 14.61 |
| Regular Market Price | 14.53 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 78,121 |
| Return On Assets | -0.34177 |
| Return On Equity | -0.93283 |
| Revenue Growth | -0.5 |
| Revenue Per Share | 0.001 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 24,505,141 |
| Shares Percent Shares Out | 0.047 |
| Shares Short | 1,151,707 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 1,220,497 |
| Short Name | Lyell Immunopharma, Inc. |
| Short Percent Of Float | 0.054899998 |
| Short Ratio | 7.09 |
| Source Interval | 15 |
| State | CA |
| Symbol | LYEL |
| Target High Price | 49.0 |
| Target Low Price | 12.0 |
| Target Mean Price | 37.875 |
| Target Median Price | 41.5 |
| Total Cash | 204,102,000 |
| Total Cash Per Share | 8.329 |
| Total Debt | 46,598,000 |
| Total Revenue | 27,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -12.6 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 20.3705 |
| Two Hundred Day Average Change | -5.840501 |
| Two Hundred Day Average Change Percent | -0.28671366 |
| Type Disp | Equity |
| Volume | 78,121 |
| Website | https://www.lyell.com |
| Zip | 94,080 |